A RELIABLE TEST FOR GASTROINTESTINAL LESIONS

胃肠道病变的可靠测试

• 批准号: 3506599
• 负责人: PAUL J LAWRENCE
• 金额: $ 26.41万
• 依托单位: LITMUS CONCEPTS, INC.
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-01-01 至 1988-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3506599
• 关键词: biotransformation; chelating agents; diagnosis quality /standard; early diagnosis; feces analysis; ferriheme; gastrointestinal hemorrhage; hemoglobin; hydrogen peroxide; neoplasm /cancer diagnosis; oxidizing agents; reagent /indicator; rectum neoplasms; solvents

Fecal Occult Blood Tests (FOBT) are routinely used to detect the blood released from GI lesions, including colorectal cancer. Colorectal cancer is the second most common serious cancer in the U.S. with 130,000 new cases and 60,000 deaths annually. Because it is slowly progressive with a long asymptomatic period, colorectal cancer provides an ideal opportunity for early detection and therapy. It is known that colorectal cancers frequently bleed, and that appropriate FOBT can be an important aid to early detection. Unfortunately, many clinical studies indicate that the most widely used commercial FOBT suffers from serious limitations in sensitivity and specificity. Proposed alternatives are no longer simple, rapid, inexpensive clinical tools. The proposed research is designed to produce the best commercial embodiment of a technically superior FOBT with significantly improved clinical performance while maintaining key user advantages.

粪便潜血试验（FOBT）通常用于检测血液 从胃肠道病变释放，包括结肠直肠癌。 结直肠癌 是美国第二常见的严重癌症，有13万新病例 每年有6万人死亡 因为它是缓慢渐进的， 无症状期，结直肠癌提供了理想的机会， 早期发现和治疗。 众所周知，结肠直肠癌 经常出血，适当的FOBT可以是一个重要的帮助， 早期检测 不幸的是，许多临床研究表明，最广泛使用的 商用FOBT在灵敏度方面受到严重限制， 的特异性 提出的替代方案不再简单、快速， 廉价的临床工具。 拟议的研究旨在产生最佳的商业实施方案 技术上的上级FOBT， 性能，同时保持关键用户优势。